Payment overview · 2025
General Payments
$1,303.84
65 reported records · 14 companies
Healthcare provider profile · identity verified
Carroll L Phillips, DNP, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MC MURRAY, PA · NPI 1003244047
Verified facts
What the public records show
CMS Open Payments records show Carroll L Phillips, DNP, CRNP received $1,303.84 in general payments during 2025 across 65 reported records.
ABBVIE INC. accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Invega Sustenna.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $230.68 | 17.7% | 9 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $166.83 | 12.8% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $153.31 | 11.8% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $137.56 | 10.6% | 10 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $105.61 | 8.1% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $97.28 | 7.5% | 5 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $97.03 | 7.4% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $71.13 | 5.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $70.31 | 5.4% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $69.52 | 5.3% | 4 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $38.55 | 3.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $33.14 | 2.5% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.96 | 1.4% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $13.93 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,303.84 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $230.68 | 9 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $166.83 | 10 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $153.31 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $137.56 | 10 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $105.61 | 6 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $105.61 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $93.64 | 5 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $83.93 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $70.31 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $61.92 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $55.57 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $47.01 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $41.71 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $38.55 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $35.11 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
165 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 449 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 329 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 12 |
| Bumetanide | Bumetanide | 272 | 14 |
| Gabapentin | Gabapentin | 266 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 251 | 12 |
| Furosemide | Furosemide | 240 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 11 |
| Metformin Hcl | Metformin Hcl | 179 | suppressed |
| Potassium Chloride | Potassium Chloride | 167 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 12 |
| Sertraline Hcl | Sertraline Hcl | 166 | suppressed |
| Eliquis | Apixaban | 165 | suppressed |
| Lisinopril | Lisinopril | 164 | 12 |
| Mirtazapine | Mirtazapine | 134 | suppressed |
| Folic Acid | Folic Acid | 125 | suppressed |
| Simvastatin | Simvastatin | 120 | suppressed |
| Spironolactone | Spironolactone | 118 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 114 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 109 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 98 | suppressed |
| Topiramate | Topiramate | 97 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | suppressed |
| Risperidone | Risperidone | 81 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 80 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 78 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 76 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 74 | suppressed |
| Allopurinol | Allopurinol | 69 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 68 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 67 | suppressed |
| Omeprazole | Omeprazole | 67 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 66 | suppressed |
| Meloxicam | Meloxicam | 65 | suppressed |
| Famotidine | Famotidine | 64 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 58 | suppressed |
| Fenofibrate | Fenofibrate | 57 | suppressed |
| Januvia | Sitagliptin Phosphate | 57 | suppressed |
| Levetiracetam | Levetiracetam | 54 | suppressed |
| Gemfibrozil | Gemfibrozil | 53 | suppressed |
| Haloperidol | Haloperidol | 53 | suppressed |
| Brilinta | Ticagrelor | 52 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 48 | suppressed |
| Perphenazine | Perphenazine | 45 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Prednisone | Prednisone | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 11 |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Auryxia | Ferric Citrate | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | 11 |
| Cephalexin | Cephalexin | 19 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Jublia | Efinaconazole | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Losartan Potassium | Losartan Potassium | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,303.84 · 65 records | ABBVIE INC. | ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, FANAPT, HETLIOZ, INGREZZA, INVEGA SUSTENNA, Jornay PM, LOREEV XR, LYBALVI, REXULTI, SPRAVATO, UZEDY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Invega Sustenna play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error